Fibrocell Appoints Alfred T. Lane, MD, Chief Medical Advisor
November 10 2016 - 8:30AM
Fibrocell Science, Inc. (NASDAQ:FCSC) today announced the
appointment of Alfred T. Lane, MD, as Chief Medical Advisor of
Fibrocell. A board certified dermatologist and pediatrician,
Dr. Lane is a Professor of Dermatology and Pediatrics (Emeritus) at
Stanford University School of Medicine and the former Chair of the
Department of Dermatology where he led a research team focused on
developing gene therapy for Epidermolysis Bullosa (EB) and other
genetic skin diseases.
“We are delighted to have Dr. Lane join
Fibrocell as our Chief Medical Advisor,” said David Pernock,
Chairman and Chief Executive Officer of Fibrocell. “Dr. Lane’s
dedication to pediatric dermatology is respected worldwide and his
commitment to helping patients and families impacted by EB and
other devastating skin diseases is remarkable. We believe his
insight will be invaluable to help us advance clinical development
of FCX-007, our gene-therapy candidate for the treatment of
Recessive Dystrophic Epidermolysis Bullosa (RDEB).”
Dr. Lane’s medical career spans four decades
with more than 25 years at the Stanford University School of
Medicine. In 1990, Dr. Lane joined the faculty at Stanford and in
1996, he was promoted to Professor of Dermatology and Pediatrics
and appointed Chair of the Department of Dermatology through 2010.
Since then Dr. Lane has focused on clinical research to develop
gene therapies for EB and other genetic skin diseases. In addition,
he is a Professor of Dermatology and Pediatrics (Emeritus) and is
affiliated with Lucile Packard Children’s Hospital at Stanford.
Dr. Lane earned his medical degree from The Ohio State
University and holds a Masters of Arts in Religious Studies from
Santa Clara University.
“I am excited to be working with Fibrocell and
to have the opportunity to contribute to the clinical development
of FCX-007,” said Dr. Lane. “I believe the Company’s use of
genetically-modified autologous fibroblasts has the potential to be
groundbreaking by addressing the underlying cause of RDEB and offer
relief to patients suffering from this progressive, debilitating
and painful genetic disease.”
About Fibrocell
Fibrocell is an autologous cell and gene therapy
company translating personalized biologics into medical
breakthroughs for diseases affecting the skin and connective
tissue. Fibrocell’s most advanced product candidate, FCX-007,
has begun a Phase I/II trial for the treatment of recessive
dystrophic epidermolysis bullosa (RDEB). Fibrocell is in
pre-clinical development of FCX-013, its product candidate for the
treatment of linear scleroderma. In addition, Fibrocell has a
third program in the research phase for the treatment of arthritis
and related conditions. Fibrocell’s gene-therapy portfolio is
being developed in collaboration with Intrexon Corporation
(NYSE:XON), a leader in synthetic biology. For more
information, visit www.fibrocell.com or follow us on Twitter at
@Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo and Fibrocell Science
are trademarks of Fibrocell Science, Inc. and/or its
affiliates. All other names may be trademarks of their
respective owners.
Forward-Looking Statements
This press release contains, and our officers
and representatives may from time to time make, statements that are
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. All statements that are not historical facts are hereby
identified as forward-looking statements for this purpose and
include, among others, statements relating to: the potential
advantages of FCX-007 and Fibrocell’s other product candidates; and
other statements regarding Fibrocell’s future operations, financial
performance and financial position, prospects, strategies,
objectives and other future events.
Forward-looking statements are based upon
management’s current expectations and assumptions and are subject
to a number of risks, uncertainties and other factors that could
cause actual results and events to differ materially and adversely
from those indicated herein including, among others: whether
pre-clinical and clinical trial results will validate and support
the safety and efficacy of Fibrocell’s product candidates; and the
risks, uncertainties and other factors discussed under the caption
“Item 1A. Risk Factors” in Fibrocell’s most recent Form 10-K filing
and Form 10-Q filings. As a result, you are cautioned not to place
undue reliance on any forward-looking statements. While Fibrocell
may update certain forward-looking statements from time to time,
Fibrocell specifically disclaims any obligation to do so, whether
as a result of new information, future developments or
otherwise.
Investor Relations Contact:
Annie Cheng
Clermont Partners
646-362-8804
acheng@clermontpartners.com
Media Relations Contact:
Karen Casey
484-713-6133
kcasey@fibrocell.com
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jul 2023 to Jul 2024